Finanzen von Iteos Therapeutics Inc (ITOS)ITOSIteos Therapeutics Inc

Evaluating the bottom line, Iteos Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -34.97%, provide a clear picture of how effectively ITOS converts its operational activities into shareholder value.

In the context of the broader market, ITOS competes directly with industry leaders such as ZYBT and PRTA. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, ITOS's gross margin of N/A stands against ZYBT's 20.51% and PRTA's 100.00%. Such benchmarking helps identify whether Iteos Therapeutics Inc is trading at a premium or discount relative to its financial performance.